Core Insights - Salarius Pharmaceuticals has clarified that its common stock continues to trade on the Nasdaq under the ticker "SLRX" despite inaccuracies reported by S&P CapIQ regarding its merger with Decoy Therapeutics and claims of delisting [1][2] Financial Overview - The company completed an underwritten public offering on November 13, 2025, raising gross proceeds of $8 million, resulting in pro forma cash of approximately $14 million [2] - The combined company has approximately 5.9 million shares of common stock outstanding [2] Business Focus - Salarius is focused on advancing Decoy's pipeline of peptide conjugate therapeutics through its IMPACT platform, which utilizes AI and machine learning for drug development [4] - The company aims to address serious unmet medical needs with its drug candidates [4] Development Plans - Over the next 12 months, Decoy plans to advance its lead asset, a pan-coronavirus antiviral, towards filing an Investigational New Drug (IND) application with the FDA [3] - Additional programs include a broad-acting antiviral for flu, COVID-19, and RSV, as well as a peptide drug conjugate targeting gastrointestinal cancers [3]

Core Insights - The strategic merger between Salarius Pharmaceuticals and Decoy Therapeutics aims to enhance the development of innovative peptide conjugate therapeutics through the IMPACT™ platform, which simplifies drug development and manufacturing processes [1][2] - The combined company has a pro forma cash position of $14 million following the merger and a recent public offering [1] Company Overview - The new entity will be named Decoy Therapeutics, with leadership including co-founders Frederick "Rick" Pierce as CEO and Barbara Hibner as Chief Scientific Officer, along with other key executives from Decoy [4] - The merger was formalized through a series of agreements, culminating in the completion of the merger on November 12, 2025, making Decoy a wholly owned subsidiary of Salarius [5] Financial and Strategic Position - Decoy has previously secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [2] - The company anticipates multiple value-creating inflection points in the coming year, focusing on unmet medical needs in respiratory infectious diseases and gastrointestinal oncology [2] Product Development Pipeline - Over the next 12 months, Decoy plans to advance its lead asset, a pan-coronavirus antiviral, towards filing an Investigational New Drug (IND) application with the FDA, alongside other antiviral programs targeting flu, COVID-19, and respiratory syncytial virus [3] Share Structure and Governance - In connection with the merger, the company issued shares of Series A and Series B Preferred Stock to former Decoy stockholders and debtholders, with a total of 4,814,106 common shares underlying these preferred shares [6] - A special stockholder meeting will be called to approve the conversion of the preferred stock into common stock [7]

Core Viewpoint - Salarius Pharmaceuticals is progressing with its merger with Decoy Therapeutics, which is expected to enhance the clinical development of innovative peptide conjugate therapeutics targeting respiratory viruses and cancer [1][3][5] Financial Highlights - For the year ended December 31, 2024, Salarius reported a net loss of $5.6 million, or $5.79 per share, a significant reduction from a net loss of $12.5 million, or $30.74 per share in 2023 [8][17] - Cash and cash equivalents decreased to $2.4 million as of December 31, 2024, down from $5.9 million a year earlier [8][15] - Total operating expenses for 2024 were $5.7 million, compared to $12.9 million in 2023, reflecting a substantial decrease in research and development spending [17] Merger Details - The merger with Decoy Therapeutics is structured such that Decoy investors will own approximately 86% of the combined company, while Salarius stockholders will own about 14%, subject to adjustments [10] - The merger aims to leverage Decoy's IMPACT™ platform for rapid design and manufacturing of peptide conjugate therapeutics, addressing unmet needs in respiratory infectious diseases and gastrointestinal oncology [3][4] Product Development - Salarius' lead candidate, seclidemstat, is currently in a Phase 1/2 clinical trial at MD Anderson Cancer Center for treating hematologic cancers, with updates expected later this year [1][4][5] - The combined company plans to integrate Salarius' SP-3164 into a targeted peptide-based PROTACS drug candidate [4]